新型コロナウイルス感染症の影響による胃がん治療薬の世界市場2020-2026:投与経路別(経口、非経口)、化学療法別、分子種類別、地域別

◆英語タイトル:Global Gastric Cancer Drugs Market Size study with COVID-19 impact, by Route of Administration (Oral. Parenteral), by Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), by Molecule Type (Small Molecule, Biologics) and Regional Forecasts 2020-2026
◆商品コード:BZW20JN001
◆発行会社(リサーチ会社):Bizwit Research & Consulting
◆発行日:2020年5月25日
◆ページ数:約200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥650,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はBizwit Research & Consulting社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Bizwit Research & Consulting社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、新型コロナウイルス感染症の影響による胃がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、投与経路別(経口、非経口)分析、化学療法別分析、分子種類別分析、地域別分析、競争状況などを含め、次の構成でお届け致します。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・新型コロナウイルス感染症の影響による胃がん治療薬の世界市場:投与経路別(経口、非経口)
・新型コロナウイルス感染症の影響による胃がん治療薬の世界市場:化学療法別
・新型コロナウイルス感染症の影響による胃がん治療薬の世界市場:分子種類別
・新型コロナウイルス感染症の影響による胃がん治療薬の世界市場:地域別
・競争状況
【レポートの概要】

Global Gastric Cancer Drugs Market is valued approximately USD 3.0 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 15.5% over the forecast period 2020-2026. Gastric cancer, also known as stomach cancer, which is characterized by an intensification of cancerous cells within the lining of the stomach. This type of cancer is usually complex to identify because in most people it normally does not show symptoms at the earlier stages. While, gastric cancer is quite rare as compared to other forms of cancer. There are some other factors of gastric cancer that include certain diseases and conditions such as lymphoma, tumors in other parts of the digestive system, stomach polyps and many more. For these reasons, several chemotherapy drugs are used to treat gastric cancer, including: 5-FU (fluorouracil), frequently given along with leucovorin (folinic acid), Capecitabine (Xeloda), Carboplatin, and many more. High incidences of gastric cancer among people owing to unhealthy diet, increasing number of obesity cases and growing elderly population are the few factors responsible for high CAGR of the market over the forecast period. For instance, the National Cancer Institute (NCI) estimated that around 28,000 new cases of stomach cancer in 2017. Also, NCI estimates that stomach cancer is about 1.7 percent of new cancer cases in the United States. Similarly, as per the GLOBOCAN 2018, the number of prevalence cases of stomach cancer in Asia was around 769,728 and is projected to grow to almost 947,186 by 2025. Although gastric cancer therapies can increase the chances of survival for patients living with gastric cancer. This, in turn, is expected to accelerate the demand of Gastric Cancer Drugs around the world. Amidst the COVID-19 outbreak across the world, the pharma industry is more concerned on the development of COVID-19 vaccine, thus, R&D efforts for gastric cancer drugs is substantially decline. Though, the demand for gastric cancer drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at significant rate in the upcoming years. However, high cost of cancer therapy and stringent regulations and policies for approval of the drugs are some other factors limiting the market growth over the forecast period of 2020-2026.

The regional analysis of global Gastric Cancer Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia-Pacific is the leading/significant region across the world in terms of market share owing to rising number of gastric cancer cases, introduction of novel therapies for metastatic gastric cancer, and the presence of larger consumer base seeking treatment, particularly in China, India and Japan. Whereas, North America is anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing R&D efforts by pharmaceuticals for gastric cancer drugs and supportive government policies in the region.

Major market player included in this report are:
AMGEN
AROG Pharmaceuticals
Ipsen Biopharmaceuticals
Array Biopharma
Taiho Oncology
AstraZeneca
ARIAD Pharmaceuticals
Eli Lilly and Company
Galena Biopharma
ASLAN Pharmaceuticals

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Route of Administration:
Oral
Parenteral

By Lines of Chemotherapy:
First-line Chemotherapy
Second-line Chemotherapy

By Molecule Type:
Small Molecule
Biologics

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017, 2018
Base year – 2019
Forecast period – 2020 to 2026

Target Audience of the Global Gastric Cancer Drugs Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

【レポートの目次】

TABLE OF CONTENTS

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Billion)
1.2.1. Gastric Cancer Drugs Market, by Region, 2018-2026 (USD Billion)
1.2.2. Gastric Cancer Drugs Market, by Route of Administration, 2018-2026 (USD Billion)
1.2.3. Gastric Cancer Drugs Market, by Lines of Chemotherapy, 2018-2026 (USD Billion)
1.2.4. Gastric Cancer Drugs Market, by Molecule Type, 2018-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Gastric Cancer Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Gastric Cancer Drugs Market Dynamics
3.1. Gastric Cancer Drugs Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Gastric Cancer Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Gastric Cancer Drugs Market, by Route of Administration
5.1. Market Snapshot
5.2. Global Gastric Cancer Drugs Market by Route of Administration, Performance – Potential Analysis
5.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Route of Administration 2016-2026 (USD Billion)
5.4. Gastric Cancer Drugs Market, Sub Segment Analysis
5.4.1. Oral
5.4.2. Parenteral
Chapter 6. Global Gastric Cancer Drugs Market, by Lines of Chemotherapy
6.1. Market Snapshot
6.2. Global Gastric Cancer Drugs Market by Lines of Chemotherapy, Performance – Potential Analysis
6.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Lines of Chemotherapy 2016-2026 (USD Billion)
6.4. Gastric Cancer Drugs Market, Sub Segment Analysis
6.4.1. First-line Chemotherapy
6.4.2. Second-line Chemotherapy
Chapter 7. Global Gastric Cancer Drugs Market, by Molecule Type
7.1. Market Snapshot
7.2. Global Gastric Cancer Drugs Market by Molecule Type, Performance – Potential Analysis
7.3. Global Gastric Cancer Drugs Market Estimates & Forecasts by Molecule Type 2016-2026 (USD Billion)
7.4. Gastric Cancer Drugs Market, Sub Segment Analysis
7.4.1. Small Molecule
7.4.2. Biologics
Chapter 8. Global Gastric Cancer Drugs Market, Regional Analysis
8.1. Gastric Cancer Drugs Market, Regional Market Snapshot
8.2. North America Gastric Cancer Drugs Market
8.2.1. U.S. Gastric Cancer Drugs Market
8.2.1.1. Route of Administration breakdown estimates & forecasts, 2016-2026
8.2.1.2. Lines of Chemotherapy breakdown estimates & forecasts, 2016-2026
8.2.1.3. Molecule Type breakdown estimates & forecasts, 2016-2026
8.2.2. Canada Gastric Cancer Drugs Market
8.3. Europe Gastric Cancer Drugs Market Snapshot
8.3.1. U.K. Gastric Cancer Drugs Market
8.3.2. Germany Gastric Cancer Drugs Market
8.3.3. Rest of Europe Gastric Cancer Drugs Market
8.4. Asia-Pacific Gastric Cancer Drugs Market Snapshot
8.4.1. China Gastric Cancer Drugs Market
8.4.2. India Gastric Cancer Drugs Market
8.4.3. Japan Gastric Cancer Drugs Market
8.4.4. Rest of Asia Pacific Gastric Cancer Drugs Market
8.5. Latin America Gastric Cancer Drugs Market Snapshot
8.5.1. Brazil Gastric Cancer Drugs Market
8.5.2. Mexico Gastric Cancer Drugs Market
8.6. Rest of The World Gastric Cancer Drugs Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. AMGEN
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. AROG Pharmaceuticals
9.2.3. Ipsen Biopharmaceuticals
9.2.4. Array Biopharma
9.2.5. Taiho Oncology
9.2.6. AstraZeneca
9.2.7. ARIAD Pharmaceuticals
9.2.8. Eli Lilly and Company
9.2.9. Galena Biopharma
9.2.10. ASLAN Pharmaceuticals
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption

List of Tables
TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL GASTRIC CANCER DRUGS MARKET
TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL GASTRIC CANCER DRUGS MARKET
TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY ROUTE OF ADMINISTRATION 2016-2026 (USD BILLION)
TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY LINES OF CHEMOTHERAPY 2016-2026 (USD BILLION)
TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY MOLECULE TYPE 2016-2026 (USD BILLION)
TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 16. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 17. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 18. GLOBAL GASTRIC CANCER DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 19. GLOBAL GASTRIC CANCER DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 20. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 21. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 22. U.S. GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 23. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 24. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 25. CANADA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 26. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 27. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 28. UK GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 29. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 30. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 31. GERMANY GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 32. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 33. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 34. ROE GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 35. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 36. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 37. CHINA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 38. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 39. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 40. INDIA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 41. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 42. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 43. JAPAN GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 44. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 45. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 46. ROAPAC GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 47. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 48. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 49. BRAZIL GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 50. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 51. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 52. MEXICO GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 53. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 54. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 55. ROLA GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 56. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 57. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 58. ROW GASTRIC CANCER DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[新型コロナウイルス感染症の影響による胃がん治療薬の世界市場2020-2026:投与経路別(経口、非経口)、化学療法別、分子種類別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆